Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

BACKGROUND: SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ferrante, Shannon Allen, Chhatwal, Jagpreet, Brass, Clifford A, El Khoury, Antoine C, Poordad, Fred, Bronowicki, Jean-Pierre, Elbasha, Elamin H
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2013
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3643851/
https://ncbi.nlm.nih.gov/pubmed/23621902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-13-190
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg